Olema Pharmaceuticals (OLMA)
(Delayed Data from NSDQ)
$9.84 USD
+0.18 (1.86%)
Updated May 17, 2024 04:00 PM ET
After-Market: $9.82 -0.02 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OLMA 9.84 +0.18(1.86%)
Will OLMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OLMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OLMA
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why
Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why
OLMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade
Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going
Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect?
Other News for OLMA
Buy Rating Affirmed for Olema Pharmaceuticals Amid Promising Clinical Trial Results for Breast Cancer Therapy
Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination
Notable Thursday Option Activity: OLMA, TRC, CRWD
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
OPEN, BCRX and AWIN among pre-market gainers